Hideki Garren

#AANAM – Ocrevus Effective in RRMS Patients with Poor Responses to Other DMTs, Early Trial Data Suggest

Early, one-year data from theĀ Phase 3 CHORDS study show that OcrevusĀ effectively prevents relapses and disease progression inĀ relapsing-remitting multiple sclerosis (RRMS) patients who have had poor responses to other disease-modifying therapies. These interim results were presented at the 2019 annual meeting of the American Academy of NeurologyĀ (AAN) in…

#AANAM – Greater Exposure to Ocrevus Means Less Risk of Disability Progression in MS Patients, Study Contends

Higher exposure to Ocrevus (ocrelizumab) is associated with greater immune B-cell depletion in the blood, and lessened risk of disability progression in patients with relapsing multiple sclerosis (MS) and primary progressive disease (PPMS), according to new research. The study supporting that finding, ā€œPharmacokinetics, Pharmacodynamics and…

Top 10 Multiple Sclerosis Stories of 2018

Multiple Sclerosis News Today brought you daily coverage of key findings, treatment developments, andĀ clinical trials related to multiple sclerosis (MS) throughout 2018. We look forward to reporting more news to patients, family members, and caregivers dealing with MS during 2019. Here are the top 10 most-read articles of…

#ECTRIMS2018 – Ocrevus Used Early in MS Course Key to Slowing Disability, Genentech Director Says

Treating patients withĀ primary progressive or relapsing multiple sclerosis (MS) early with Ocrevus (ocrelizumab) is key to slowing disease progression, according to Hideki Garren, global head of Multiple Sclerosis and Neuroimmunology at Genentech. In an interview withĀ Multiple Sclerosis NewsĀ TodayĀ at the recentĀ 34thĀ congress of the European Committee for Treatment…

New Ocrevus Data, Post-FDA Approval, Supports Range of Benefits, Genentech’s Hideki Garren Says

OcrevusĀ (ocrelizumab), Genentechā€™sĀ humanized anti-CD20 monoclonal antibody, continues to show clear evidence that it helps to slow disease progression and enable better function ā€” including in the hands and limbs ā€” ofĀ relapsing multiple sclerosis (MS)Ā and primary progressive multiple sclerosis (PPMS), latest data reveals. TheĀ first FDA-approved therapy ā€” in March…

New Ocrevus Findings Show Benefits to Range of MS Patients: Interview with Genentech’s Dr. Hideki Garren

Genentech shared new insights into the workings of Ocrevus (ocrelizumab) and its effectiveness in reducing disease activity and slowing progression in relapsing and primary progressive multiple sclerosis (MS) at the recent 3rd Congress of the European Academy of Neurology (EAN). The new findings, previously reported here, built on analyses of information gathered during the three Phase 3 clinical trials assessing Ocrevus' safety and efficacy, as well as through monitoring patients in extension studies. The studies showed that nearly 40 percent of Ocrevus-treated relapsing patients and nearly 30 percent of primary progressive patients achieved NEPAD during the Phase 3 trials. In contrast, only 21.5 percent of those treated with Rebif and 9.4 percent receiving placebo achieved NEPAD ā€” figures that demonstrate Ocrevusā€™ impact on patientsā€™ lives, as well as Ocrevusā€™ ability to slow the decline in walking ability and other types of disabilities are comparable between patients with relapsing and primary progressive disease ā€” data that demonstrate that the treatment acts on disease mechanisms that drive disability in both disease forms. How these effects play out in the long-term is the subject of ongoing research, as Genentech continues to follow these patients in an extension study. In addition, Ocrevus' prescription label strongly advises against pregnancy while on the treatment. Despite precautions, some women became pregnant during the trials. One of the meeting presentations narrated outcomes of these pregnancies; one healthy baby born at term and two ongoing pregnancies in women exposed to the drug. But while Genentech monitors women who become pregnant while on Ocrevus, the number of reported pregnancies is too small to draw conclusions about the treatmentā€™s safety in pregnancy, and researchers do not know if Ocrevus also depletes B-cells in the fetus or in the baby born to a treated woman.

Ocrevus Phase 3 Trial Will Explore How Treatment Works by Viewing Changes in Spinal Fluid

Already an approved treatment for relapsing and primary progressive multiple sclerosis (MS), Ocrevus (ocrelizumab) is still undergoingĀ scrutiny in several clinical trials. MostĀ focus on the drugā€™s effects in specific patient groups, but one studyĀ aims to advanceĀ understanding ofĀ how Ocrevus works to harness disease. To do so, the open-label Phase 3…

Ongoing Ocrevus Trials Seek More Knowledge of Treatment Effects and MS Patients’ Benefits

Ocrevus (ocrelizumab), a recently approvedĀ therapy for relapsing and primary progressive multiple sclerosis (MS),Ā is now on the U.S. market, but research intoĀ itsĀ use is far from over. Several clinical trials, sponsored by Ocrevus’ developer Genentech or its parent company Roche, are looking at various aspectsĀ of the treatment. Multiple Sclerosis…